India's efforts to produce and supply life-saving drugs at affordable prices face challenges from multinational companies trying to “evergreen” their patents. THE average life expectancy across the globe has increased from around 30 years a century ago to over 65 years today. This has been made possible in large part by modern medicine. Never before in history have humans had access to such an array of medicines and devices to...
More »SEARCH RESULT
Question of efficacy -Leena Menghaney
The country is clearly shaping its legislation to promote access to medicines by fostering generic production. INDIA'S approach to the revision of its Patents Act in 2005 is a clear example of a country shaping its legislation to promote access to medicines by fostering generic production. Although World Trade Organisation (WTO) rules made it mandatory for India to put in place a patent regime for medicines by 2005, nothing obliges...
More »Western warnings-R Ramachandran
India is coming under increasing pressure from the U.S. and the European Union for the strict patentability criteria it applies for medicines. AS was only to be expected, the two landmark decisions made by the Indian patent office in recent times concerning pharmaceutical patent cases have not gone down well with the multinational drug industry. First, there was the rejection in 2006 of the patent application by the Swiss multinational...
More »Sights on licence to drive, not kill-Sobhana K
The government is planning to tighten the rules for issuing and renewing driving licences to make the process “fudge proof” after a study showed drivers’ fault accounted for most road accidents in the country. A committee of state transport commissioners and officials from the National Informatics Centre recently came up with suggestions on possible amendments to the rules. The panel, headed by Andhra Pradesh transport commissioner Hiralal Samariya, has submitted its report...
More »A Strike against Pharma MNCs
-Economic and Political Weekly The Compulsory licence for Nexavar is only the beginning of a new battle over drug prices. The grant of a Compulsory licence (CL) to Natco Pharma, a relatively small Indian pharmaceutical company, to manufacture and sell the cancer drug sorafenib (Nexavar) has been rightly hailed as a major step forward for public health and the wider availability of life saving medicines. The German pharmaceutical company Bayer holds the patent...
More »